Compare ARVN & MSBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | MSBI |
|---|---|---|
| Founded | 2015 | 1881 |
| Country | United States | United States |
| Employees | N/A | 861 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 603.7M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | MSBI |
|---|---|---|
| Price | $8.04 | $30.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 3 |
| Target Price | $15.05 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 680.3K | 129.5K |
| Earning Date | 05-04-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 5.00% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $2.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $14.24 |
| 52 Week High | $14.22 | $30.51 |
| Indicator | ARVN | MSBI |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 68.58 |
| Support Level | $7.35 | $27.07 |
| Resistance Level | $10.18 | $30.34 |
| Average True Range (ATR) | 0.41 | 0.77 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 70.20 | 87.19 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.